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ABSTRACT
Background    Postoperative complications have been 
shown to worsen prognoses of various cancer types. 
Methods    We retrospectively analyzed 265 patients 
with stage II-III gastric cancer who underwent curative 
gastrectomies between 1991 and 2010 at Tottori Uni-
versity Hospital to determine the effect of postoperative 
intra-abdominal complication (IAC) on prognosis. 
Results    Of the 265 patients, 38 (14.3%) developed 
postoperative IACs of grade ≥ 2, of whom significantly 
more patients were male. Patients in the IAC group were 
significantly older than patients in the non-complication 
(NC) group. The NC group had significantly better sur-
vival than did the IAC group (P < 0.0001). Within the 
IAC group, 5-year survival rates did not significantly 
differ between patients with infectious complication sub-
group (24.6%) and the non-infectious subgroup (46.2%). 
Grade of complication was not related to prognosis. 
Lengths of time before starting adjuvant chemotherapy 
(AC) after surgery were significantly longer for the IAC 
group (55.3 ± 34.7 days) than for the NC group: (26.6 ± 
11.9 days; P = 0.0023). Prognosis of patients who took 
AC within 6 weeks after surgery tended to be better than 
that of patients who took AC > 6 weeks after surgery (P 
= 0.071). In multivariate analysis, IAC was an indepen-
dent predictor of prognosis, as were age, invasion depth, 
and lymph node metastasis.
Conclusion    Postoperative IACs were related to poorer 
survival for patients with stage II–III gastric cancer.
Key words    gastrectomy; gastric cancer; postoperative 
complication; prognosis
Although the prognosis of patients with gastric carci-
noma has improved with increased availability of diag-
nostic techniques and better intraoperative and postop-
erative care, death from gastric cancer (GC) still ranks 
second among all cancer deaths worldwide.1 
 Gastrectomy with D2 lymph node dissection has 
been the standard treatment for advanced GC in Japan,2 
and has led to lower morbidity and mortality rates. 
However, as D2 lymph node dissection and esopha-
go-jejunostomy after total gastrectomy are technically 
demanding, some patients suffered from postoperative 
complications,3 which can worsen their short-term out-
come (such as lengthening their hospital stay, or requir-
ing longer fasting). Furthermore, some complications, 
such as anastomotic leakage and pancreatic fistula, may 
become serious or even life-threatening.
 Reportedly, postoperative complications also neg-
atively affect long-term outcomes for a wide range of 
cancers,4–7 including GC.8, 9 However, reports regarding 
GC have included only infectious complications and 
excluded non-infectious complication in their analyses. 
Adjuvant chemotherapy (AC) is an indispensable com-
ponent of treatment, aimed at preventing recurrence in 
patients with resectable advanced GC. The Japanese 
Gastric Cancer Treatment Guideline recommends ad-
juvant therapy by S-1 for 1 year after curative surgery,2 
based on the Adjuvant Chemotherapy Trial of TS-1 for 
Gastric Cancer (ACTS-GC), which showed a survival 
benefit from AC after D2 gastrectomy compared with 
surgery alone for patients with stage II–III GC.10 They 
also recommend starting AC within 6 weeks after oper-
ation. Late initiation of AC has been significantly associ-
ated to poor prognosis in patients with stage II–III GC.11 
Therefore, both non-infectious and infectious complica-
tions are likely to worsen their prognoses, owing to late 
initiation of AC. However, few reports have yet shown 
a correlation between non-infectious complications and 
prognosis in GC patients. This retrospective study was 
designed to determine the effect of postoperative in-
tra-abdominal complications (IACs), including both in-
fectious and non-infectious complications on long-term 
outcomes in patients with stage II–III GC.
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MATERIALS AND METHODS
Patients 
This study included consecutive 265 patients with stage 
II–III gastric adenocarcinoma who underwent cura-
tive gastrectomies (R0 resections) between 1991 and 
2010 at the Tottori University Hospital. Institutional 
review board approval was obtained (1607A052), and 
the informed consent requirement was waived for this 
study. All patients underwent distal partial gastrectomy, 
proximal partial gastrectomy or total gastrectomy with 
regional lymph node dissection. At the time of analysis, 
the median follow-up for the 129 remaining survivors 
was 91 months. Of the 136 deaths, 86 were related to 
recurrence of GC, two to another malignancy and 48 to 
another disease or accident. 
 With regard to AC, 72 patients underwent chemo-
therapy, while the remainder did not. Uracil-tegafur 
(UFT, Taiho, Tokyo, Japan) was used in 16 patients and 
tegafur-gimeracil-oteracil (S-1, Taiho) was used in 56 
patients. These patients received 200–400 mg of UFT, 
2–3 × daily orally, or 80 mg/m2/day oral S-1. These reg-
imens were administered for 6 months to a year postop-
eratively. Because S-1 became available for the treatment 
of gastric cancer in 1999, UFT was mainly used before 
1999 and S-1 was used after 1999.
 Clinicopathological findings were generally de-
termined according to the 14th edition of the Japanese 
Classification of Gastric Carcinoma.12 With regard to the 
definition of postoperative IACs, the Clavien–Dindo (CD) 
system was used to classify each patient’s postoperative 
IAC.13, 14 If an individual patient had multiple complica-
tions, the highest grade was used in the analysis. Grade 
1 complications were not evaluated to exclude the possi-
bility of a description bias in the patient records.
Statistical analysis 
For statistical analyses, chi-square and Fisher’s exact 
probability tests were used to compare distribution of 
individual variables between patient groups. Differences 
between the two groups were evaluated using the Mann–
Whitney U test. Disease-specific survival (DSS) was 
calculated by the Kaplan–Meier method and compared 
using the log-rank test. Patients who died of causes other 
than GC were considered lost to follow-up at the time of 
death for DSS. We used multivariate analysis of factors 
considered prognostic of DSS, with a Cox’s proportion-
al hazards model and a stepwise procedure. P < 0.05 
was considered significant. Statistical analyses were 
performed with SPSS for Windows version 19.0 (SPSS, 
Chicago, IL). 
RESULTS
Table 1 shows details of complications in patients in-
cluded in the current study. Thirty-eight patients (14.3%) 
developed postoperative IACs of grade 2 or higher 
according to CD classification. Of these patients, 5.3% 
developed grade III IACs and 1.5% had grade IV or V 
IACs.
 Table 2 shows the differences in clinicopathological 
characteristics between the IAC group (n = 38) and the 
NC group (n = 227). The IAC had a significantly higher 
percentage of male patients, and had a significantly older 
median age, than did the NC group. The IAC and NC 
groups did not significantly differ in tumor size, depth of 
invasion, lymph node metastasis, pathological stage of 
disease, tumor location, type of gastrectomy, and sple-
nectomy. 
 Five-year survival rates differed significantly be-
tween the IAC group (34.5%) and the NC group (70.7%; 
P < 0.0001; Fig. 1). Within the IAC group, 5-year surviv-
al rates did not significantly differ between the subgroup 
with infectious IACs (24.6%) and those with non-infec-
tious IACs (46.2%; P = 0.4; Fig. 2). Five-year survival 
also did not significantly differ between the subgroup 
with grade 2 IACs (40.2%) and those with grade 3–5 
IACs (33.9%; P = 0.39; Fig. 3). 
 Intervals before starting AC after surgery differed 
significantly between the IAC group (55. 3 ± 34.7 days; 
n = 10) and the NC group (26.6 ± 11.9 days; n = 62; P = 
0.0023). Because the Japanese Gastric Cancer Treatment 
Guideline recommends starting AC with S-1 within 6 
weeks post-surgery in patients with stage II–III GC, 
we divided patients who took AC into the non-delayed 
group (patients who started AC within 6 weeks of sur-
gery), and the delayed group (who started AC later than 
6 weeks after surgery). In the NC group, only 4 patients 
(6.5%) were in the delayed group, while 5 patients (50%) 
were in the delayed group in the IAC group and the 
difference was statistically significant (P = 0.0001). The 
prognosis of patients in non-delayed group tended to be 
better than that in delayed group, but not significantly 
so (P = 0.071; Fig. 4). Two anti-cancer drugs, UFT and 
S-1, were used for AC in the current study. Patients who 
took UFT and those who took S-1 showed no significant 
difference in prognosis (P = 0.24, Fig. 5).
 We finally applied Cox proportional hazard model and 
a stepwise procedure on age, sex, tumor size, histology, 
tumor location, depth of invasion, lymph node metastasis, 
lymphatic vessel invasion, blood vessel invasion, type of 
gastrectomy, splenectomy, AC, and IAC, to identify inde-
pendent prognostic factors. Multivariate analysis indicated 
that IAC was an independent prognostic indicator, as were 
age, depth of invasion, and lymph node metastasis (Table 3).
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Table 1. Details of postoperative intra-abdominal complications
Grade of CD classifications
Type of complication II IIIa IIIb IVa IVb V Total
Infectious complication
Pancreatic fistula 3 2 1 1 0 1 8
Anastomotic leakage 8 6 0 0 0 1 15
Wound infection 2 0 0 0 0 0 2
Non-infectious complication
Stenosis 4 4 0 0 0 0 8
Ileus 3 0 0 0 0 1 4
Afferent loop syndrome 0 0 1 0 0 0 1
Total 20 12 2 1 0 3 38
CD, Clavien–Dindo.
Table 2. Clinicopathologic characteristics of patients with stage II–III gastric cancer by the presence of 
intra-abdominal complications
Complication group (n = 38) Non-complication group (n = 227) P value
Gender 0.014
Male 30 132
Female 8 95
Age (years) 71.2 + 11.5 65.9 + 12 0.011
Tumor size (cm) 7.6 + 4.2    6.5 + 3.5 0.18
Tumor location 0.52
Upper 14 64
Middle 11 82
Lower 13 81
Tumor depth 0.7
T1 3 10
T2 6 43
T3 12 61
T4 17 113
Histology 0.74
Differentiated 16 89
Undifferentiated 22 138
Lymph node metastasis 0.2
N0 5 47
N1 9 79
N2 10 40
N3 14 61
Pathological stage 0.67
II 15 98
III 23 129
Gastrectomy 0.25
Distal 13 109
Proximal 1 8
Total 24 110
Splenectomy 0.36
Performed 10 45
Not performed 28 182
Adjuvant chemotherapy 0.89
Performed 10 62
Not performed 28 165
N0, no regional lymph node metastases; N1, metastasis in 1–2 regional lymph nodes; N2, metastasis in 3–6 regional lymph nodes; N3, 
metastasis in 7 or more regional lymph nodes; T1, tumor has invaded lamina propria or submucosa; T2, tumor has invaded the muscularis 
propria; T3, tumor has invaded the subserosa; T4, tumor invasion is contiguous to or exposed beyond the serosa or tumor invades adjacent 
structures.
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Table 3. Multivariate analysis using Cox’s proportional hazards model and a stepwise procedure to identify 
independent prognostic factors for disease-specific survival
Covariates P value Hazard ratio 95% CI
Age*  0.019 1.024 1.004–1.045
Depth of invasion (T1–T4)† < 0.0001 1.942 1.437–2.625
Lymph node metastasis (N0–N3)‡ < 0.0001 1.545 1.265–1.887
Intra-abdominal complication    0.0001 2.633 1.610–4.305
*Continuous variable. †T1: tumor has invaded lamina propria or submucosa; T2: tumor has invaded the muscularis propria; T3: tumor 
has invaded the subserosa; T4: tumor invasion is contiguous to or exposed beyond the serosa or tumor invades adjacent structures. ‡N0: 
no regional lymph node metastases; N1: metastasis in 1–2 regional lymph nodes; N2: metastasis in 3–6 regional lymph nodes; N3: metas-
tasis in 7 or more regional lymph nodes. CI, confidence interval. 
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Fig. 1. Survival curves for patients with 
stage II–III gastric cancer, based on pres-
ence of postoperative intra-abdominal 
complications. Patients without intra-ab-
dominal complication had significantly 
better prognosis than did patients with in-
tra-abdominal complications (P < 0.0001).
Fig. 2. Survival curves for patients with 
stage II–III gastric cancer and postopera-
tive intra-abdominal complications. Out-
comes did not significantly differ between 
patient subgroups with infectious and 
non-infectious intra-abdominal complica-
tion (P = 0.4).
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Fig. 3. Survival curves for patients with 
stage II–III gastric cancer with postop-
erative intra-abdominal complication by 
grade of complication (CD classification). 
Outcomes did not significantly differ be-
tween patients with grade 2 intra-abdom-
inal complications and those with grade ≥ 
3 complications (P = 0.39). CD, Clavien–
Dindo.
Fig. 4. Survival curves for patients with 
stage II–III gastric cancer with postoper-
ative intra-abdominal complication based 
on length of time before starting AC. Prog-
nosis of patients who started AC within 6 
weeks after surgery tended to be better (but 
not significantly so) than that of patients 
who started AC more than 6 weeks after 
surgery (P = 0.071). AC, adjuvant chemo-
therapy.
Fig. 5. Survival curves for patients with 
stage II–III gastric cancer and postopera-
tive intra-abdominal complication by drugs 
used for adjuvant chemotherapy. Prognosis 
did not significantly differ between patients 
who took UFT and those who took S-1 (P 
= 0.24). S-1, tegafur-gimeracil-oteracil; 
UFT, tegafur-uracil.
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DISCUSSION
Gastric surgery has had lower morbidity and mortality 
rates in recent years because of advances in treatment 
techniques, surgical devices, and perioperative manage-
ment.15–17 In fact, a recent clinical trial indicates that 
the rate of overall surgery-related complications among 
patients who underwent gastrectomy with D2 lymph-
adenectomy—the current standard operation for ad-
vanced GC—is 20.9%, including 2.3 % for anastomotic 
leakages, 5.3% for pancreatic fistulae, 5.3% for abdomi-
nal abscesses, and 4.6% for pneumonia, and with an 0.8% 
hospital death rate.3
 Postoperative complications inversely affect patients’ 
short-term outcomes, and some complications, such as 
anastomotic leakage and pancreatic fistula, can become 
life-threatening. Therefore, every effort should be made 
to avoid their development. They have also been shown 
to affect long-term outcomes of patients with various 
cancer types.4–7 We have clearly demonstrated that post-
operative IAC is significantly associated with poorer 
survival of patients with stage II–III GC in this current 
study. Other reports have also associated infectious com-
plications to poor prognosis in GC patients.8, 9 Tokunaga 
et al. compared the prognosis of patients with stage II–
III GC with and without infectious IACs and found that 
postoperative infectious IACs adversely affected overall 
and relapse-free survival of these patients9; Tokuna-
ga et al. considered pancreas-related complications, 
anastomotic leakages, and intra-abdominal abscesses 
as infectious IACs, but excluded ileus and wound in-
fections, whereas all type of IACs were included in the 
current study. Notably, we found that both infectious 
and non-infectious IACs were related to poor prognosis. 
The reason why IACs are related to poor prognosis re-
mains unclear. With regard to infectious complications, 
immune suppression might be a factor in poor surviv-
al. We have previously reported that number of total 
lymphocytes significantly decreased after gastrectomy 
for GC although some inflammation markers, such as 
numbers of white blood cells and neutrophils and serum 
CRP levels, significantly increased.18 The lymphocyte 
count reached a minimum on postoperative day (POD) 
1 and then increased to preoperative level on day 30. 
Prolonged inflammation could have induced prolonged 
suppression of cell-mediated immunity in patients with 
infectious IACs, which would put those patients at high 
risk of recurrence. 
 Non-infectious IACs are also associated with poor 
survival. In this regard, delayed initiation of AC might 
worsen survival of patients with non-infectious IAC. In 
the current study, time before starting AC after surgery 
differed significantly in the IAC group (55.3 ± 34.7 days) 
and the NC group (26.6 ± 11.9 days). As the aim of AC 
is to eradicate micrometastatic tumor cells, delaying 
AC allows such cells to grow after operation. Some 
clinicians often believe that chemotherapy may there-
fore have little or no adjuvant benefit after a 3-month 
delay19, 20 Time before initiating AC has been associated 
with survival in breast and colorectal cancers,20, 21 and 
recently, in prognosis for advanced GC patients who 
started S-1 AC within or after 6 weeks post-surgery.11 
As postoperative complications are a common reason for 
delaying AC, the poorer prognosis in our IAC group is 
likely due to delayed AC. 
 The present retrospective study has limitations. 
First, clinicopathological factors differed between the 
IAC and NC groups. As pathological stage is considered 
to be the strongest prognostic clinicopathological factor 
for GC after curative gastrectomy,22, 23 we conducted 
multivariate analysis and found IACs to be an indepen-
dent prognostic factor. Second, the degree of immune 
suppression was not assessed in this study, but should be 
examined in a future trial to verify our hypothesis that 
patients with intra-abdominal infectious complications 
have severe immune suppression that leads to high re-
currence rates and poor overall and relapse-free survival 
rates. Third, the two anti-cancer drugs that were used for 
AC in the current study, UFT and S-1, were mainly used 
before 2003 and after 2004, respectively. Those two 
drugs may have differently affected the patients’ prog-
noses. In this regard, patients who took UFT and those 
who took S-1 did no significantly differ in prognosis, 
which indicates that the differences of the two drugs’ ef-
fects on outcomes was small for patients included in the 
current study. 
 In conclusion, our study clearly shows that postoper-
ative IACs—both infectious and non-infectious—are re-
lated to poor survival of patients with stage II–III gastric 
cancer. Therefore, every effort should be made to avoid 
the development of these complications.
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